Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | US

Overview

Corporate Details

ISIN(s):: US2528281080 (+1 more)
LEI:
Country:: United States of America
Address:: 7 TIMES SQUARE, 10036 NEW YORK
Website:: https://dianthustx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Icure Pharmaceutical Incorporation Develops transdermal patches for dementia/Parkinson's and offers cosmetic ODM/OBM services.	South Korea	175250
Idorsia Ltd Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.	Switzerland	IDIA
IGC Pharma, Inc. Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.	United States of America	IGC
IL DONG PHARMACEUTICAL CO., LTD. Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.	South Korea	249420
ILSUNG IS CO., LTD. Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.	South Korea	003120
ILYANG PHARMACEUTICAL CO.,LTD Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.	South Korea	007570
I-Mab A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.	United States of America	IMAB
ImageneBio, Inc. A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.	United States of America	IMA
IM Cannabis Corp. International producer of medical-grade cannabis for patients and providers in Israel and Germany.	United States of America	IMCC
Immatics N.V. Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.	United States of America	IMTX